This is the text extract for Consultation on a proposal regarding doxepin hydrochloride and salbutamol, browse documents here.

---

16 November 2007 To all interested parties

Consultation on a proposal regarding doxepin hydrochloride and salbutamol

PHARMAC and Pacific Pharmaceuticals have entered into a provisional agreement regarding doxepin hydrochloride (Anten) and salbutamol (Respigen), and PHARMAC is seeking feedback on this proposal. Outline of proposal Under this proposal, there would be: § § § a price and subsidy increase for doxepin hydrochloride (Anten), with the effect that all available presentations would be fully subsidised; a listing of Respigen as an alternative salbutamol aerosol inhaler; and reference pricing of the Salamol and Ventolin brands of salbutamol aerosol inhaler to Respigen.

Further details of this proposal are provided below. Feedback sought PHARMAC welcomes feedback on this proposal. If you wish to submit feedback on this proposal please submit them in writing by 30 November 2007 to: Sean Dougherty Therapeutic Group Manager PHARMAC PO Box 10-254 Wellington 6143 Details of proposal § The price and subsidy for doxepin hydrochloride (Anten) would be increased as follows from 1 February 2008 (ex-manufacturer, excluding GST):

Current subsidy (price, if different from subsidy) $4.99 $4.19 ($5.20) $6.99 Proposed subsidy and price $5.24 $5.46 $7.34

Email: Sean.Dougherty@pharmac.govt.nz Fax: (04) 460 4995

Chemical Doxepin hydrochloride Doxepin hydrochloride Doxepin hydrochloride

Formulation Cap 10 mg Cap 25 mg Cap 50 mg

Pack size 100 100 100

A164650 - T07-106

---

§

Please note that manufacture of the 75 mg capsule of doxepin hydrochloride has been discontinued and will likely be unavailable from 1 July 2008 (delisted from the Pharmaceutical Schedule from 1 January 2009). Respigen (salbutamol) would be listed in Section B of the Pharmaceutical Schedule from 1 June 2008 at the following price and subsidy (ex-manufacturer, excluding GST):

Proposed subsidy and price $3.80

§

Chemical Salbutamol

Brand Respigen

Formulation Aerosol inhaler, 100 µg per dose CFC-free

Pack size 200 dose OP

§

PHARMAC would reduce the subsidy payable for the existing brands of salbutamol aerosol inhaler by reference pricing them to Respigen from 1 June 2008 as follows:

Current subsidy (price, if different from subsidy) $4.00 $4.00 ($6.00)

Chemical

Brand

Formulation

Pack size

Proposed subsidy

Salbutamol

Salamol

Aerosol inhaler, 100 µg per dose CFC-free Aerosol inhaler, 100 µg per dose CFC-free

200 dose OP

$3.80

Salbutamol

Ventolin

200 dose OP

$3.80

If you have any questions in relation to this proposal, please contact me on (04) 916 7534 or by email: Sean.Dougherty@pharmac.govt.nz. Yours sincerely

Sean Dougherty Therapeutic Group Manager

A164650 - T07-106

2